Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

(2020) P. Cahn et al.   Journal of Infection and Public Health

Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCDID Cohort

(2020) Aoife Lacey et al.   AIDS

Efectos adversos neuropsiquiátricos de dolutegravir en la práctica clínica real

(2020) Marina Povar-Echeverría et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada

(2020) Kassem Bourgi et al.   Journal of the International AIDS Society

Factors associated with weight gain in people treated with dolutegravir

(2020) Lucia Taramasso et al.   Open Forum Infectious Diseases

Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine

(2020) Jade Soldado-Folgado et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Changes in weight and body mass index with first-line doravirine-based therapy

(2020) Orkin Chloe et al.   AIDS

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

(2019) Annalisa Mondi et al.   Journal of the International AIDS Society

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

(2019) Hanh Thi Pham et al.   EXPERT OPINION ON PHARMACOTHERAPY

Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy

(2019) Kassem Bourgi et al.   CLINICAL INFECTIOUS DISEASES

Homeostatic model assessment for insulin resistance index trajectories in HIV‐infected patients treated with different first‐line antiretroviral regimens

(2019) Nicola Gianotti et al.   JOURNAL OF MEDICAL VIROLOGY

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients

(2019) Matthew Radford et al.   AIDS

Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice

(2019) Arturo Ciccullo et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study

(2019) Barbara Rossetti et al.   ANTIVIRAL RESEARCH

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

(2019) Yali Wang et al.   Expert Opinion on Drug Metabolism & Toxicology

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

(2019) Lucia Taramasso et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

(2019) Jean-Michel Molina et al.   Lancet HIV

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection

(2019) Pedro Cahn et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

(2018) Joseph J. Eron et al.   AIDS

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

(2018) Emma D. Deeks   DRUGS

Doravirine

(2018) Marie-Alice Colombier et al.   Current Opinion in HIV and AIDS

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals

(2018) Andrew M. Hill et al.   Current Opinion in HIV and AIDS

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

(2018) Lene Ryom et al.   Lancet HIV

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017

(2018) Mario Gomez et al.   INFECTION

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

(2018) A Borghetti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

(2018) Nicola Squillace et al.   Drug Design Development and Therapy

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

(2018) Antonella d’Arminio Monforte et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature

(2017) Bo Wang et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Tolerability of integrase inhibitors in a real-life setting

(2017) Judit Peñafiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

(2017) Pedro Cahn et al.   Journal of the International AIDS Society

Weight Gain: A Possible Side Effect of All Antiretrovirals

(2017) Lucia Taramasso et al.   Open Forum Infectious Diseases

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice

(2016) Antonio Di Biagio et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2016) Robert Güerri-Fernández et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2016) David Wohl et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

(2016) Steve Kanters et al.   Lancet HIV

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance

(2015) Amedeo Capetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

(2015) Nina Friis-Møller et al.   European Journal of Preventive Cardiology

Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin

(2014) Martine Auclair et al.   ANTIVIRAL THERAPY

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

(2014) Matt S Anderson et al.   ANTIVIRAL THERAPY

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Evaluation of the Effect of Cobicistat on theIn VitroRenal Transport and Cytotoxicity Potential of Tenofovir

(2013) Kirsten M. Stray et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues

(2013) G. Guaraldi et al.   HIV CLINICAL TRIALS

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects

(2012) Justin Koteff et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Abacavir use and cardiovascular disease events

(2011) Mario Cruciani et al.   AIDS

Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

(2011) Andrew M. Hall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy

(2009) Mark Nelson et al.   AIDS

Tenofovir-associated renal and bone toxicity

(2009) CLN Woodward et al.   HIV MEDICINE